Cidel Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.8M Buy
19,854
+186
+0.9% +$190K 1.15% 24
2026
Q1
$18.1M Sell
19,668
-5,465
-22% -$5.54M 0.99% 31
2025
Q4
$27M Sell
25,133
-1,593
-6% -$1.52M 1.91% 14
2025
Q3
$20.4M Buy
26,726
+5,591
+26% +$4.16M 1.17% 27
2025
Q2
$16.5M Buy
21,135
+5,476
+35% +$4.26M 0.99% 33
2025
Q1
$12.9M Buy
15,659
+96
+0.6% +$79.9K 0.85% 43
2024
Q4
$12M Buy
15,563
+2,874
+23% +$2.38M 0.81% 44
2024
Q3
$11.2M Buy
12,689
+2,667
+27% +$2.4M 0.79% 42
2024
Q2
$9.07M Buy
10,022
+9,378
+1,456% +$7.5M 0.7% 44
2024
Q1
$501K Sell
644
-123
-16% -$87.5K 0.04% 184
2023
Q4
$447K Buy
+767
New +$448K 0.02% 200

Other funds holding LLY

Cidel Asset Management's LLY Position: Q2 2026 in Review

Cidel Asset Management increased its Eli Lilly (LLY) stake by 0.95% in Q2 2026, buying an estimated $190K and bringing the position to 19,854 shares worth $23.8M. The position accounts for 1.15% of the portfolio, ranked #24.

Cidel Asset Management first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. The position peaked at $27M in Q4 2025. 4,618 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cidel Asset Management held 19,854 shares of Eli Lilly worth $23.8M as of Q2 2026.
  • Cidel Asset Management bought 186 Eli Lilly shares in Q2 2026, an estimated $190K.
  • Eli Lilly made up 1.15% of Cidel Asset Management's portfolio in Q2 2026, its #24 holding.
  • Cidel Asset Management first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • Cidel Asset Management's Eli Lilly position peaked at $27M in Q4 2025.
  • 4,618 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cidel Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.